You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The new Series B investment was made by Northpond Ventures, with previously invested $20 million in the Australian diagnostics company.
The firm submitted its Verigene II Gastrointestinal Flex Assay to the FDA in Q4 and expects to submit Verigene II Respiratory Flex Assay to the agency in Q1 2020.
The Seoul-based firm said its PCR-based test kit is the first novel coronavirus assay to be granted emergency use authorization in Korea.
PacBio will try to take the Sequel II to the clinic in China with the help of Berry Genomics and is open to partnerships globally, including with Illumina.
Sienna will provide sales, marketing, and technical support training to Immuno Diagnostics staff, as well as establish a reference lab.
The South Korean company has now received CE marking for its hepatitis B, hepatitis C, and HIV-1 detection kits, which run on its ExiStation system.
The new laboratory, which began trial operations this week, is designed to test 10,000 samples per day for the 2019-nCoV coronavirus.
The firm is lowering its guidance due to anticipated revenue loss related to remediation efforts associated with its Alaris pump system.
The deal with Quaphaco includes minimum Unyvero A50 instrument and infectious disease test cartridge purchases of €1.9 million over the initial three-year term.
Contributing to the Japanese diagnostic firm's higher revenues were increased instrument and reagent sales both domestically and internationally.